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Levels of human immunodeficiency virus (HIV) DNA, RNA, or p24 antigen and reverse transcriptase activity 
in T-cell cultures treated with 500 IU of recombinant alpha interferon (rIFNa) per ml were comparable to those 
in control cultures. Radioimmunoprecipitation analysis of proteins in lysates of IFN-treated T cells documented 
a marked accumulation of HlV proteins. Localization of gp120 by immunofluorescence showed a diffuse 
pattern in IFN-treated cells quite distinct from the ring pattern in untreated control cells. That large quantities 
of a 1 2 0  in aberrant cell compartments might affect HlV morphogenesis was confirmed in infectivity studies: 
virions from IFN-treated cells were 100- to 1,000-fold less infectious than an equal number of virions from 
control cells. Direct examination of IFN-treated and control HW-infected cells by transmission electron 
microscopy showed little difference in the number or distribution of viral particles. However, quantitation of 
a 1 2 0  by immunogold particle analysis revealed a marked depletion of envelope glycoprotein in virions released 
from IFN-treated cells. This defect in gp120 assembly onto mature viral particles provides a molecular basis for 
this loss of infectivity. 
Clinical and experimental observations support a central 
role for alpha interferon (IFN-a) in the regulation of human 
immunodeficiency virus (HIV) replication (2, 5-7, 9-11, 
1616,  23, 25, 26, 28, 31, 32, 34, 35). High-titer viremia with 
HIV present in both plasma and cells is evident during acute 
infection. Within weeks of the onset of symptoms, HIV 
viremia falls to low levels. IFN levels in plasma directly 
correlate with viral load during this acute viral syndrome (32, 
35). Clinical trials of exogenous IFN-a in early HIV disease 
show a significant reduction in the level of p24 antigen (Ag) 
in the plasma of treated subjects and less AIDS-associated 
opportunistic infection (15). Such preliminary evidence for 
antiviral efficacy in patients is matched by other reports that 
document the potent antiviral activity of IFN in HIV- 
infected T-cell and monocyte cultures (7, 9, 10, 14, 23, 25, 
30). HIV infection of monocytes is completely inhibited by 
IFN-a administered prior to or at the time of viral challenge 
(9, 14). HIV-infected monocytes treated with IFN-a after 
infection show little or no viral gene expression. However, 
and in contrast to the antiviral effects seen in monocytes, the 
effects of IFN-a on HIV replication in T cells are less 
dramatic (7, 9, 25, 30, 33, 34). A number of studies show no 
changes in viral gene expression following IFN-treatment of 
HIV-infected T cells. Although most investigators agree that 
the principal effect of IFN in T cells is on the terminal stage 
of the HIV life cycle, there is little accord as to the exact 
nature of this effect (7, 9, 23, 25, 30, 33). We describe in this 
* Corresponding author. 
report an IFN-associated defect in the assembly of gp120 
onto mature viral particles that accounts for significant loss 
of virion infectivity. This assembly defect provides a novel 
molecular basis for IFN-associated antiviral effects on HIV 
replication in T cells. 
To measure the effect of IFN-a on levels of HIV DNA and 
RNA in infected T cells, peripheral blood mononuclear cells 
isolated from whole blood by Ficoll-diatrizoate density gra- 
dient centrifugation were cultured in RPMI 1640 (GIBCO, 
Grand Island, N.Y.) with 1 kg of phytohemagglutinin (PHA; 
Sigma Chemical Co., St. Louis, Mo.) per ml, 10% partially 
purified human interleukin-2 (IL-2; Advanced Biotechnolo- 
gies Inc., Col'umbia, Md.), and 15% heat-inactivated fetal 
calf serum (Sterile Systems, Inc., Logan, Utah) for 3 days. 
PWL-2- t rea ted  T cells were exposed to HIV-l,,~,,,, 
(Advanced Biotechnologies) at a multiplicity of infection of 
0.01 infectious virus per target cell with and without 500 IU 
of rIFN-a,, per ml (a generous gift from Schering-Plough 
Research Laboratories, Inc., Kenilworth, N.J.). All virus 
stock and reagents were free of mycoplasma (Gen-probe 11; 
Gen-probe Inc., San Diego, Calif.) and bacterial endotoxin 
contamination. Culture medium was half exchanged every 2 
to 3 days for 2 weeks. Cell lysates of HIV-infected T cells 
were extracted with phenol and chloroform-isoamyl alcohol, 
and the DNA was precipitated with ethanol. Polymerase 
chain reaction amplification of HIV-specific DNA sequences 
with nucleotide primers from the 5' long terminal repeat and 
gag genes and 2.5 U of Tag polymerase (Cetus Corp., 
Emeryville, Calif.) per ml was performed on 1 kg of total 
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FIG. 1. Effect of IFN-a on levels of HIV DNA and RNA in 
14-day HIV-l,nv.,IIB-infected T cells. HIV gag  DNA was ampli- 
fied by the polymerase chain reaction. Levels of DNA for the 
IFN-a, gene in cell lysates served as a reference for comparison 
between samples. HIVgag RNAwas subjected to reverse transcrip- 
tion and polymerase chain reaction amplification of the cDNA 
transcripts. mRNA for glyceraldehyde 3-phosphate dehydrogenase 
(GAPDH) was used as an internal reference to allow analysis of 
RNA between different samples. 
cellular DNA with an automatic cycler (Perkin Elmer-Cetus, 
Emeryville, Calif.). The products of 25 cycles were analyzed 
by Southern blot hybridization after agarose gel electropho- 
resis with a radiolabeled DNA probe specific for a gag 
sequence internal to the primer pairs. Levels of DNA for the 
IFN-a* gene in cell lysates served as a reference for 
comparisons between samples (9). Total RNA was extracted 
from cell lysates with acidic guanidinium isothiocyanate- 
phenol-chloroform. Levels of viral and cellular RNA were 
estimated after reverse transcription with antisense primers 
and polymerase chain reaction amplification of the cDNA 
transcripts. The mRNA for the cellular enzyme, glyceralde- 
hyde 3-phosphate dehydrogenase served as internal refer- 
ence to allow analysis of RNA between different samples. 
Initial studies showed that HIV-1 replication in T cells was 
only minimally affected by exposure to recombinant IFN-a 
(rIFN-a). We and others show that even concentrations of 
rIFN-a as high as 10,000 IU/ml will not prevent infection of 
primary T cells or T-cell lines by HIV (9, 30, 33). Further- 
more, levels of HIV DNA and RNA in 14-day HIV-1- 
infected T cells treated with 500 IU of rIFN-a per ml at the 
time of infection and throughout 2 weeks of culture were no 
different from those in untreated control cells (Fig. 1). 
Similarly, levels of p24 Ag and reverse transcriptase (RT) 
activity in the same cultures are comparable (<twofold 
difference). Levels of p24 Ag and RT activity in T-cell 
cultures treated with 500 IU of rIFNa per ml were 89% + 2% 
and 74% 2 6% (mean 2 standard error of the mean [SEMI 
for three different experiments), respectively, of those in 
control cultures 12 to 15 days after HIV infection. 
More detailed analysis of p24 Ag and RT activity levels in 
IFN-treated cells revealed a marked difference in the local- 
ization of these viral proteins (Table 1). Less than 10% of p24 
Ag in cultures of HIV-infected T cells was found in cell 
lysates 2 weeks after infection (7% 2 3% [mean 2 SEM for 
three experiments]). In contrast, levels of p24 Ag in lysates 
of HIV-infected T cells treated continuously with rIFN-a for 
TABLE 1. Effect of IFN-a on levels of HIV p24 Ag and RT 
activity in culture fluids and lysates of infected T cellsa 
Level (%) of p24 Ag RT activity (%) 
{nn/ml) in: (1@ c~m/ml) in: ~- , . . ,  
Culture fraction 
Control Cells with Control Cells with 
cells IFN-u cells IFN-a 
- 
Culture fluids 78 (90%) 67 (76%) 34.4 (96%) 27.3 (84%) 
Cell lysate 9 (10%) 21 (24%) 1.3 (4%) 5.2 (16%) 
Total 87 88 35.7 32.5 
- 
" PWLZ-treated T cells infected with HIV-I,,.,,,, were cultured with 
and without 500 IU of rIFNa per ml for 2 weeks. Levels of p24 Ag in culture 
fluids and freeze-thaw cell lysates were determined in triplicate by enzyme-lied 
immunosorbent assay (E. I.  Du Pont de Nemours & Co., Biierica, Mass.). RT 
activity was estimated by incorporation of ['HIdTP into DNA transcripts of 
polyr(A) (9). Radioactivity was estimated by liquid scintillation spectroscopy. 
HIV-1 stock served as positive control for p24 Ag and RT activity. 
2 weeks were 24% of the total p24 Ag level in these cultures 
(23% 2 1% [mean 2 SEM for three experiments]). Indeed, 
although there was no difference in total p24 Ag levels 
between IFN-treated and control cells, the level of cell- 
FIG. 2. Effect of IFN-a on levels of HIV proteins in infected T 
cells. PHAnL-2-treated T cells infected with HIV-l,v,IIB were 
cultured with and without 0 to 500 IU of rIFN-a Der ml for 2 weeks. 
All cultures were exposed to 250 kCi of ["~]meihionine for 3 h and 
then washed. Radiolabeled HIV-s~ecific   rote ins were isolated from 
cell lysates with pooled HIV-s&opositjve sera bound to protein 
~-sepharose CL-4s (Phannacia).  he immune complexeg were 
washed and boiled; immunoprecipitated proteins were analyzed by 
sodium dodecyl sulfate-pol~acryfamide gel electrophoresis-and a i -  
toradiography (1, 32). 
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FIG. 3. Effect of IFNa on the distribution of gpl20 in HIV-infected T cells. PHML-2-treated T cells infected with HIV-l,v~II,B were 
cultured with and without 500 IU of rIFN-a per ml for 2 weeks. Cells were washed, fixed in acetone, and exposed to goat anti-HIV-l,, gp120 
(12) (provided by N. Haigwood, Chiron Corp.). Treated cells were washed after a reaction time of 1 h on ice and then resuspended for another 
1 h in fluorescein isothiocyanate-conjugated rabbit anti-goat immunoglobulin G (Sigma). Washed cells were examined by epi-illumination 
fluorescence microscopy (18). (A) Uninfected control cells. (B and C) HIV-infected T cells cultured with (panel C) and without (panel B) 
IFN-a. Magnification, x250. 
associated p24 Ag in IFN-treated cultures was threefold 
higher than that in control cultures. Localization of RT 
activity in cultures of IFN-treated cells followed a similar 
pattern. Again, only 3% of RT activity in cultures of HIV- 
i control 
?' 
HIV (relative concentration) 
FIG. 4. Effect of IFN on infectivity of progeny virus from HIV- 
infected primary T cells. PWCZtreated T cells infected with 
HIV-l, at a multiplicity of infection of 1 were cultured with and 
without 500 IU of r1FN-a per ml. Seven days after infection, virus in 
fluids of control and IFN-treated cultures was pelleted by ultracentrif- 
ugation and adjusted to equal levels of RT activity. Fourfold viral 
dilutions were added to uninfected PWG2-treated T cells. Levels of 
RT activity in culture fluids (mean of triplicate determinations) are 
shown 10 days after infection. The SEM for the triplicate determina- 
tions for each point was less than 10% of the mean value. 
infected T cells was found in cell lysates 2 weeks after 
infection (3% + 1% [mean 2 SEM for three experiments]). 
Most RT activity was released into the culture fluid. Virtu- 
ally all of this RT activity was virion associated and was 
recovered in the pellet after ultracentrifugation. Levels of 
RT activity in lysates of T cells treated continuously with 
rIFN-or for 2 weeks were 15% of the total RT activity in these 
cultures (15% + 1% [mean 2 SEM for three experiments]). 
Cell-associated RT activity in IFN-treated cultures was four- 
to fivefold higher than that in control cultures. 
The preceding data documented an accumulation of viral 
proteins and virions within IFN-treated T cells. This accu- 
mulation was confirmed by radioimmunoprecipitation anal- 
ysis of viral proteins in cell lysates 2 weeks after infection 
(Fig. 2). The total amount of HIV protein in lysates of 
IFN-treated cells increased directly with the IFN concentra- 
tion. It is important to note that processing of HIV proteins 
(relative levels of gp160 and gp120 or p55 and p24) in 
IFN-treated and control cells at this level of analysis was 
comparable (Fig. 2). 
Further evidence that IFN treatment of infected T cells 
induced accumulation of viral proteins within the cell is 
strikingly illustrated in immunofluorescence studies for 
gp120 (Fig. 3). HIV-infected T cells showed a characteristic 
ring pattern for gp120; virtually all of this processed HIV 
envelope glycoprotein was at or on the plasma membrane. In 
contrast, the identical cells treated continuously with IFN 
for 2 weeks showed a bright and diffuse pattern for gp120. 
Previous reports show that about 10% of gp160 in T cells is 
cleaved to produce gp120. Most gp160 (85 to 95%) is 
transported to and degraded in lysosomes (32). In the 
absence of IFN treatment, gp120 is transported to the 
plasma membrane without degradation and assembled into 
mature virions. IFN treatment markedly affects this trans- 
port process by mechanisms presently unknown, so that 
gp120 or unprocessed gp160 becomes diffusely localized 
throughout the cell. Interestingly, radioimmunoprecipitation 
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FIG. 5. Effect of IFN-u on envelope gp120 of virions from HIV-infected H9 cells. H9 cells (provided by R. C. Gallo, National Institutes 
of Health) infected with HIV-l,,.,,,, were cultured with and without 500 IU of rIFN-u per ml for 2 weeks and then exposed to goat 
anti-HIV-l,, gp120 (12) for 2 h at room temperature. Antibody-treated cells were washed and exposed to rabbit anti-goat immunoglobulin 
G-gold conjugate (10-nm gold particles; Amersham International, Amersham, United Kingdom) for 2 h at room temperature. Unbound gold 
particles were removed after washing. Cells were lixed in 2.5% glutaraldehyde, postlixed in 1% osmium tetroxide, en block stained, 
dehydrated in ethanol, and embedded in SPURR's plastic resin. After polymerization, blocks were cut, and 50- to 70-nm sections were placed 
on copper grids and poststained with lead citrate (22). Grids were examined in a JEOL l00B electron microscope. (A) Virions from control 
HIV-infected H9 cells. (B) Virions from IFN-treated cells. Magnification, ~73,000. 
analysis showed that the relative amounts of gp160 and 
a 1 2 0  were not changed by IFN treatment. This suggests 
that gp120 is not degraded in its altered cellular compart- 
ment. 
Accumulation of a 1 2 0  in alternative cell compartments 
during IFN treatment suggested that this envelope compo- 
nent may not be freely available for virus assembly. We 
examined this hypothesis by performing a direct analysis of 
virions released from IFN-treated T cells. Progeny virions in 
culture fluids of IFN-treated and control cells 2 weeks after 
virus infection were adjusted to equal levels of RT activity 
and assayed for infectivity on PHA/IL-2-treated T cells (Fig. 
4). Virions from IFN-treated cells were at least 1,000-fold 
less infectious than an equal number of virions from control 
cells. Such loss of infectivity was confirmed in three repli- 
cate experiments and in a syncytial plaque assay with 
CEM-SS cells (20). Again, virions from IFN-treated cells 
were 100- to 1,000-fold less infectious than an equal number 
of virions from control cells. 
The most direct evidence that virions from IFN-treated T 
cells were deficient in envelope a 1 2 0  came from transmis- 
sion electron-microscopic studies with immunogold-labeled 
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anti-gpl20 (Fig. 5). HIV virions were numerous at the 
plasma membrane 12 days after virus infection. The immu- 
nogold label delineated obvious virion-associated gp120 on 
most viral particles. In a survey of 225 individual virions, the 
average number of gold particles per virion was 5.5 2 0.4 
(mean 2 SEM). In contrast, virions from the identical cells 
treated continuously with IFN showed a marked reduction 
in the amount of gp120. There was no appreciable change in 
the number or distribution of virions at the plasma mem- 
brane of IFN-treated cells, but the number of gold particles 
per virion was 0.5 ? 0.1 (mean + SEM for 122 virions), a 
reduction of 91%. A replicate experiment showed 10.5 gold 
particles per virion with control T cells 11 days after HIV 
infection versus 0.9 gold particles per virion (a reduction of 
91%) from the same cells treated with 500 IU of rIFN-a per 
ml. Experiments with H9 cells, a continuous T-cell line, 
infected with HIV-l,,~,,,, and cultured with and without 
rIFN-or for 10 days showed changes in virion-associated 
gp120 of similar magnitude. The number of gold particles per 
virion in cultures of H9 cells was 1.4 + 0.2 (mean 2 SEM for 
140 virions). Virions from IFN-treated H9 cells had only 0.2 
2 0.1 gold particle per virion (mean 2 SEM for 82 virions), 
a reduction of 86%. Another experiment with H9 cells 
showed 4.5 gold particles per virion in control cells 8 days 
after HIV infection versus 0.7 gold particle per virion (a 
reduction of 85%) in cells treated with 500 IU of rIFN-a per 
ml. These studies document a profound and selective deple- 
tion of HIV envelope gp120 on the virions released from 
IFN-treated infected T cells and provide a molecular basis 
for the loss of infectivity. 
A major antiviral effect of IFN for inhibition of HIV 
replication in T cells operates in the stages of virus assembly 
and release (30,33). There is general agreement that the rate 
and extent of viral protein synthesis change little during IFN 
treatment of chemically HIV-infected T cells (7, 9, 30, 33). 
Other antiviral effects of rIFN-a were demonstrated during 
acute infection of T cells with HIV-1 (12a, 28). However, the 
numbers of progeny virus released from infected cells are 
reproducibly decreased for both primary T cells from blood 
and continuous T-cell lines (7, 9, 28, 30, 33). Certain inves- 
tigators find decreased numbers of virions budding into 
extracellular spaces (30); others report a marked accumula- 
tion of viral particles at the cell surface (33). We confirm this 
effect of IFN on HIV replication in T cells. Synthesis of HIV 
DNA, RNA, and protein was minimally affected, even by 
high concentrations of IFN administered continuously 
throughout the culture interval. Indeed, the morphology and 
number of virions at the plasma membrane in IFN-treated 
and control HIV-infected cells were indistinguishable by 
transmission electron microscopy. However, these analyses 
underestimate the potent effects of IFN on HIV morphogen- 
esis. Virions released from IFN-treated T cells were 100- to 
1,000-fold less infectious than an equal number of virions 
from control cells. The basis for this dramatic change resides 
in an assembly defect for gp120 onto the mature viral 
- - 
particle. 
The effects of IFN on HIV morphogenesis in T cells has 
precedent in other viral systems (8, 17-19, 24). Progeny 
vesicular stomatitis virus (a rhabdovirus) and murine leuke- 
mia virus (a retrovirus) from infected cells treated with 
IFN-a are much less infectious than are virions from control 
cells (3, 13, 17-19, 21, 24,27, 29). Analysis of progeny virus 
from IFN-treated vesicular stomatitis virus-infected cells by 
transmission electron microscopy documents a marked de- 
crease in glywprotein envelope spikes (17-19). Transport of 
the vesicular stomatitis virus envelope glycoprotein to the 
plasma membrane is inhibited by IFN-a. Immunofluores- 
cence studies show accumulation of envelope glycoprotein 
in Golgi complexes: endoglycosidase digestion experiments 
suggest an IFN-a-associated block in envelope glycoprotein 
transport through the trans Golgi (4, 29). Similarly, changes 
in the infectivity of murine leukemia viruses are directly 
related to IFN-a-induced alterations of viral envelope gly- 
coprotein processing and assembly (3). These fundamental 
observations provide a sound basis for exploration of IFN- 
associated defects in gp120 assembly in HIV-infected T 
cells. Studies directed at mechanisms of gp160 cleavage, 
transport of gp120 through the Golgi complex, and assembly 
of gp120 onto the core virion at or near the plasma mem- 
brane are directed at key areas of investigation. Careful 
definition of the site and mechanism of IFN action should 
allow better design of alternate therapeutic agents that act at 
this vulnerable stage of the HIV life cycle. 
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